MTOR and cancer: Since mTOR based regimens lead to Treg expansion [16–18] which can be considered an undesirable effect in the treatment of cancer, strategies that can selectively deplete Tregs might improve the antitumor effect of mTOR inhibitors by reversing the suppressive effect on the immune system.